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Background: In the 1980s, Streptococcus pneumoniae and Haemophilus 
influenzae were identified as the principal causes of severe pneumonia in 
children. We investigated the etiology of severe childhood pneumonia in 
Kenya after introduction of conjugate vaccines against H. influenzae type b, 
in 2001, and S. pneumoniae, in 2011.
Methods: We conducted a case–control study between August 2011 and 
November 2013 among residents of the Kilifi Health and Demographic 
Surveillance System 28 days to 59 months of age. Cases were hospitalized 
at Kilifi County Hospital with severe or very severe pneumonia according 
to the 2005 World Health Organization definition. Controls were randomly 
selected from the community and frequency matched to cases on age and 
season. We tested nasal and oropharyngeal samples, sputum, pleural fluid, 
and blood specimens and used the Pneumonia Etiology Research for Child 
Health Integrated Analysis, combining latent class analysis and Bayesian 
methods, to attribute etiology.
Results: We enrolled 630 and 863 HIV-uninfected cases and controls, 
respectively. Among the cases, 282 (44%) had abnormal chest radiographs 
(CXR positive), 33 (5%) died in hospital, and 177 (28%) had diagnoses 
other than pneumonia at discharge. Among CXR-positive pneumonia cases, 
viruses and bacteria accounted for 77% (95% CrI: 67%–85%) and 16% 
(95% CrI: 10%–26%) of pneumonia attribution, respectively. Respiratory 
syncytial virus, S. pneumoniae and H. influenza, accounted for 37% (95% 
CrI: 31%–44%), 5% (95% CrI: 3%–9%), and 6% (95% CrI: 2%–11%), 
respectively.
Conclusions: Respiratory syncytial virus was the main cause of CXR-pos-
itive pneumonia. The small contribution of H. influenzae type b and pneu-
mococcus to pneumonia may reflect the impact of vaccine introductions in 
this population.
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Pneumonia is the leading cause of death in children <5 years of age in developing countries.1 Streptococcus pneumoniae and 
Haemophilus influenzae were the main causes of severe pneumonia 
and the principal pathogens against which treatment is targeted in 
the Integrated Management of Childhood illness guidelines.2
H. influenzae type b (Hib) vaccine and the 10-valent pneu-
mococcal conjugate vaccine (PCV10) were introduced into the 
Kenya National Immunization Program in November 2001 and 
January 2011, respectively. In Kilifi, invasive disease caused by 
Hib declined by 88% in the 3 years after the vaccine was intro-
duced3 and this was sustained for a further 9 years.4 PCV10 was 
introduced in Kilifi with a catch-up campaign for children 12–59 
months of age to accelerate herd protection.5 At the end of 2011, 
vaccine coverage in children 2–11 months (≥2 doses) and 12–59 
months (≥1 dose) was 80% and 66%, respectively.6 By 2016, the 
incidence of invasive pneumococcal disease caused by vaccine 
serotypes declined by 92% among children <5 years of age6; the 
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incidence of radiologically confirmed pneumonia and clinically 
defined pneumonia declined by 48% and 27%, respectively.7
Given the success of these vaccines across the world,8–10 the 
etiologic profile of childhood pneumonia is expected to change fol-
lowing their introduction. The remaining pathogens are likely to 
be more diverse, and current treatment strategies against childhood 
pneumonia are likely to be ineffective. We need to direct new drug 
and vaccine development against the remaining pathogens.11,12
The Pneumonia Etiology Research for Child Health 
(PERCH) study was a 7-country case–control study evaluating the 
etiology of pneumonia among hospitalized children in developing 
countries.13 In Kilifi, PERCH was nested within the Kilifi Health 
and Demographic Surveillance System (KHDSS), which has con-
ducted long-term surveillance of invasive bacterial diseases and 
viral respiratory pathogens for 2 decades. Kilifi is typical of much 
of rural sub-Saharan Africa, with low HIV prevalence, a mature 
Hib vaccine program and a recent PCV program.
STUDY POPULATION AND METHODS
Study Site
KHDSS covers an area of 891 km2 around Kilifi County 
Hospital (KCH) located on the Kenya Coast and follows a popu-
lation of approximately 270,000 for vital events and migration, 
through 4 monthly household visits. Hospitalization at KCH, 
including electronic clinical and laboratory records, is captured in 
the KHDSS database through real-time linkage of each patient to 
the KHDSS population register.14
Kilifi County has a predominantly rural population of sub-
sistence farmers, 58% of whom live below the National poverty 
line.15 It has 2 rainy seasons: April to July and October to Decem-
ber.16 Malaria transmission peaks during the rainy seasons, but 
overall, malaria has been declining over the last 15 years.17 Under 
5 and infant mortality ratios in the KHDSS were 34.6 and 23.4 per 
1000 live births, respectively, between 2011 and 2013. Pneumonia 
and malaria were the principal causes of death among infants and 
children 1–4 years of age, respectively, between 2008 and 2011.18 
Annual HIV prevalence estimates among women attending ante-
natal screening at KCH were 2.6%–3.2% between 2011 and 2013. 
The prevalence of wasting, underweight and stunting (given as Z 
scores of <−2 SD in weight-for-height, weight-for-age and height-
for-age) were 4%, 17% and 39%, respectively, in children <5 years 
of age in Kilifi County.19
Selection of Participants
All pediatric admissions to KCH from August 15, 2011, to 
November 15, 2013, were screened for eligibility. Clinical officers 
assessed most children at the outpatient clinic; very sick children, 
or those presenting out of hours, were assessed on the pediatric 
wards. Study clinicians examined all admissions and recorded 
clinical data directly onto a standardized computer record. Chil-
dren 28 days to 59 months of age, resident within the KHDSS and 
admitted with clinical features of 2005 World Health Organization 
(WHO)-defined severe or very severe pneumonia, were eligible to 
participate.20,21 Eligibility was assessed in real time by a computer 
algorithm applying PERCH inclusion and exclusion criteria (Table, 
Supplemental Digital Content 1, http://links.lww.com/INF/D871).
Between December 7, 2012, and February 11, 2013, recruit-
ment was interrupted by a nationwide nurses’ strike which closed 
the general pediatric ward. During this time, recruitment was 
restricted to very sick children in the High Dependency Unit. The 
study was extended by 3 months (August 16 to November 15, 2013) 
to compensate for this interruption.
Controls were selected randomly from the KHDSS popu-
lation register. Children were eligible if they did not have WHO-
defined severe or very severe pneumonia. They were frequency 
matched to cases by age and season but with a minimum monthly 
recruitment target of 25 controls. We visited a homestead ≥3 times 
before concluding that the selected control was unavailable and 
choosing a replacement from the random list. For controls, enrol-
ment and sample collection was done at participants’ homes.
Clinical Samples and Laboratory Analyses
At admission, blood samples were collected for culture, 
serology, microscopic examination for malaria parasites, and poly-
merase chain reaction (PCR) to detect S. pneumoniae. Rapid HIV 
antibody testing was done as part of routine care. Nasopharyngeal 
and oropharyngeal swab (NPOP) samples were collected within 8 
hours of admission for PCR testing using a 33-pathogen multiplex 
quantitative PCR (FTD Resp-33; Fast-track Diagnostics, Sliema, 
Malta) and pneumococcal culture (NP swabs only). Induced spu-
tum (IS) samples, for culture, Mycobacterium tuberculosis (MTB) 
and PCR testing, were collected within 24 hours of admission. In 
children with suspected MTB, a second IS sample was collected 
for additional MTB testing 48 hours after admission or a gastric 
aspirate sample where IS was clinically contraindicated. Pleu-
ral fluid samples were collected for culture and PCR in children 
where a pleural tap was clinically indicated. Lung aspirates were 
not obtained. CXRs were obtained from cases at the earliest oppor-
tunity after admission and interpreted by a trained reading panel.22 
CXRs were classified as abnormal if there was presence of any of 
consolidation, pleural effusion or other infiltrate. Abnormal CXRs 
are referred to here as CXR positive. All samples collected in cases 
were also collected in controls, with the exception of blood for 
culture, pleural fluid and IS. Data on antibiotic use were available 
from clinical records and serum bioassay results.
Study staff were trained on clinical examination and sam-
ple collection using a standardized training curriculum.23 Samples 
were processed and analyzed using standardized laboratory meth-
ods.24 Data-derived density thresholds were applied to PCR results 
for S. pneumoniae, H. influenzae, Pneumocystis jirovecii and cyto-
megalovirus to optimize sensitivity and specificity.25 –27
At discharge, a nonstudy clinician recorded up to 2 discharge 
diagnoses (primary and secondary) into a standardized computer 
record, selecting the most appropriate diagnoses from a predefined 
list. Cases of pneumonia were classified here as lower respiratory 
tract infections (LRTI). Cases of bronchiolitis were classified sep-
arately. A senior clinician audited all the discharge diagnoses to 
ensure consistency of recordings.
Statistical Analysis and Data Management
Electronic clinical data were exported monthly to a central 
coordinating center which undertook data management and statisti-
cal analyses for all participating sites.28
The fraction of pneumonia due to each pathogen was esti-
mated using the PERCH Integrated Analysis (PIA) method, which 
is described in detail elsewhere.29–31 In brief, the PIA is a Bayesian 
nested partially latent class analysis that integrates the results for 
each case from blood culture, NP/OP PCR, whole blood PCR for 
pneumococcus and IS culture for MTB. The PIA also integrates test 
results from controls to account for imperfect test specificity of NP/
OP PCR and whole blood PCR. All analyses were adjusted for age 
(<1 versus ≥1 year) to account for differences in pathogen preva-
lences by this factor. The model assumes that each child’s pneumo-
nia was caused by a single pathogen. The PIA estimated both the 
individual- and population-level etiology probability distributions, 
each summing to 100% across pathogens where each pathogen 
has a probability ranging from 0% to 100%. The population-level 
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etiologic fraction estimate for each pathogen was approximately the 
average of the individual case probabilities and was provided with a 
95% credible interval (95% CrI), the Bayesian analogue of the con-
fidence interval. The sensitivity priors used in the model are pre-
sented in Table, Supplemental Digital Content 11 (http://links.lww.
com/INF/E465). Odds ratios (OR) and 95% confidence intervals 
(CI) of pathogens detected on NP/OP PCR in cases compared with 
controls were calculated using logistic regression adjusted for age 
in months and presence of all other pathogens detected on NP/OP 
PCR to account for associations between pathogens. Because the 
WHO clinical case definitions have relatively poor specificity for 
true lung infection, the primary etiology analysis was restricted to 
pneumonia cases with abnormal CXRs. We also restricted to HIV-
uninfected cases because the etiology of pneumonia is different in 
HIV-positive cases.32
A separate integrated etiology model was run with in-hospital 
vital status as a covariate, adjusting for the child’s age. This links the 
mortality status of the child with the etiology assigned at each itera-
tion of the analysis. To calculate the case fatality ratio (CFR) of res-
piratory syncytial virus (RSV), the proportion of children who died 
among all those assigned to RSV is calculated at each iteration of the 
analysis, and those CFRs are averaged across all iterations to obtain 
an overall CFR and the distribution of the iteration-specific CFRs is 
used to calculate a 95% CrI. This is similarly done for all the remain-
ing (non-RSV) cases at each iteration to obtain a non-RSV CFR.
We described the primary hospital-assigned discharge diag-
noses among all admissions (28 days to 59 months of age) and 
among PERCH cases and used LRTI recorded in either primary 
or secondary discharge diagnoses to estimate specificity of the 
PERCH pneumonia case definition.
Descriptive statistical analyses were performed using SAS 
9.3 (SAS Institute, Cary, NC), and the integrated etiology analysis 
was performed using R Statistical Software 3.3.1 (The R Devel-
opment Core Team, Vienna, Austria) and Bayesian inference soft-
ware JAGS 4.2.0 (http://mcmc-jags.sourceforge.net/). The R pack-
age used to perform the PERCH Integrated Analysis, named the 
Bayesian Analysis Kit for Etiology Research, is publicly available 
at https://github.com/zhenkewu/baker.
Ethics
We obtained written informed consent from parents or legal 
guardians of all participants. The Kenya Medical Research Insti-
tute Ethical review committee and the Oxford University Tropical 
Research Ethics Committee approved the study.
RESULTS
Study Participants
Of 7545 children admitted to KCH in the study period, 2202 
were KHDSS residents 28 days to 59 months of age; of these, 832 
had severe or very severe pneumonia, 784 were eligible for inclu-
sion in PERCH, and 634 were enrolled (Fig. 1). The proportion 
who agreed to participate varied by location (72%–100%) and was 
lowest among urban dwellers in Kilifi town (Table, Supplemental 
Digital Content 2, http://links.lww.com/INF/D872). Among those 
who were eligible, those who were enrolled did not differ by age, 
sex and pneumonia defining features or in-hospital mortality from 
those who were not (Table, Supplemental Digital Content 3, http://
links.lww.com/INF/D873). The incidence of enrolment to PERCH 
was higher in locations located closer to KCH (Figure, Supplemen-
tal Digital Content 4, http://links.lww.com/INF/D874).
Of 1369 children invited to participate as controls, 889 
(65%) were screened and 877 (64%) were eligible, of whom 865 
(99%) were enrolled (Fig. 1). Controls were well matched to cases 
on age and season (Table 1).
Clinical Characteristics
Four (0.6%) cases and 2 (0.2%) controls were HIV positive 
and were excluded from further analyses. Clinical characteristics of 
HIV-uninfected cases are presented in Table 2. CXRs were obtained 
in 96% (602/630); of the 28 cases without a CXR, 5 died before a 
CXR was obtained. Eight cases had CXRs obtained >72 hours after 
admission and were excluded from analyses restricted or stratified 
by CXR findings. Among the 594 remaining cases, 282 (47%) were 
CXR positive.
Laboratory Results
Blood was cultured in 629 (99.7%) cases; a pathogen was 
isolated in 10 (1.6%) cases overall and in 9 (3.2%) CXR-positive 
cases (Table, Supplemental Digital Content 5, http://links.lww.
com/INF/D875). These included 5 S. pneumoniae, 2 H. influenzae 
nontype b, and one each of Staphylococcus aureus, Pseudomonas. 
aeruginosa (isolated in a child with a normal CXR) and a mixed 
infection with Salmonella species and Streptococcus Group A in 
1 child. A contaminant was cultured in 51 (8.1%) samples. In all 
4 HIV-positive cases, blood cultures were negative. Three pleural 
fluid samples were collected: 1 was positive for S. pneumoniae by 
culture and PCR; and 2 were positive for S. aureus by culture. Of 
the 596 IS specimens, 2 (0.3%) were positive for Mycobacterium 
tuberculosis by culture; one of these cases was CXR positive (Table, 
Supplemental Digital Content 5, http://links.lww.com/INF/D875).
In the NPOP samples, at least 1 pathogen was detected by 
PCR in 99% (588/628) of cases and 98% (813/855) of controls. 
The median number of NPOP pathogens detected per case and per 
control was 4 (IQR: 3–4) and 3 (IQR: 2–4), respectively (Table, 
Supplemental Digital Content 6, http://links.lww.com/INF/D876). 
Among 581 cases with available data on time and date of antibi-
otic administration at admission, NPOP specimens were collected 
before antibiotic administration in 355 (58%). There was seasonal 
variation in the isolation of RSV, rhinovirus, human metapneumo-
virus and parainfluenza virus 1–4 (Figure, Supplemental Digital 
Content 7, http://links.lww.com/INF/D877). NPOP and whole 
blood PCR findings are presented in Table, Supplemental Digital 
Content 8, http://links.lww.com/INF/D878.
Etiology Results
In the PIA model, the main causes of CXR-positive pneu-
monia were viruses (77%; 95% CrI: 67%–85%), with RSV being 
the most common (37%; 95% CrI: 31%–44%, Fig. 2A–2D and 
Table, Supplemental Digital Content 9, http://links.lww.com/INF/
D879). H. influenzae (6%; 95% CrI: 2%–11%) and S. pneumoniae 
(5%; 95% CrI: 3%–9%) were the most common bacterial causes 
(Fig. 2A and Table, Supplemental Digital Content 9, http://links.
lww.com/INF/D879). Among those over 1 year of age, rhinovi-
rus was the most common pathogen (29%; 95% CrI: 18%–42%, 
Fig. 2B and Table, Supplemental Digital Content 9, http://links.
lww.com/INF/D879). The CFRs for RSV and non-RSV cases were 
1.6 (95% CrI: 0–4.4) and 8.1 (95% CrI: 6.4–9.6), respectively.
Discharge Diagnoses
LRTI was a primary discharge diagnosis in 25% of all 
admissions and 66% of WHO-defined severe or very severe 
PERCH cases (Fig. 3). Among PERCH cases, 28% (177/634) were 
not assigned LRTI in either their primary or secondary discharge 
diagnosis (Table, Supplemental Digital Content 10, http://links.
lww.com/INF/D880). The percentage without LRTI was higher for 
very severe pneumonia (42%, 135/324) than for severe pneumonia 
Awori et al The Pediatric Infectious Disease Journal • Volume 40, Number 9S, September 2021
S32 | www.pidj.com © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. 
(14%, 42/310, P < 0.005). Among 284 CXR-positive cases, 42 
(15%) did not have a discharge diagnosis of LRTI (Fig. 3 and Table, 
Supplemental Digital Content 10, http://links.lww.com/INF/D880), 
including 23 (8%) whose CXRs showed consolidation or effusion 
according to the radiologic reading standard.33
DISCUSSION
Using an integrated analysis of all available etiology data, 
we found that viruses accounted for 77% of the attribution of 
CXR-positive pneumonia among HIV-uninfected children with 
WHO-defined severe or very severe pneumonia in Kilifi, Kenya. 
RSV and rhinovirus were the commonest viral causes accounting 
for 37% and 14%, respectively. S. pneumoniae and H. influenzae, 
which were the main causes of radiologically confirmed pneumonia 
(consolidation with or without pleural effusion) in the prevaccine 
era, accounted for only 11% of CXR-positive cases (consolidation, 
infiltrates or pleural effusion) in our study.
In the Kilifi PERCH site, and also in Bangladesh, the propor-
tion of pneumonia attributed to viruses, 77% and 78%, respectively, 
was substantially higher than the average across the 7 PERCH sites 
(61%).31 We undertook a pilot study for the PERCH methods in 
Kilifi among children 1–59 months of age between January and 
December 2010.34 In the pilot study, a cause was determined in 
only 33% of pneumonia cases: virus-only infections in 25%, bacte-
rial only in 6% and mixed viral-bacterial infections in 1% of cases 
in an analysis of blood culture and NP sample results. The pilot 
study was typical of previous etiology research in that children 
with no positive tests were designated “unknown cause” and in our 
study they accounted for 67% of all cases investigated. In the main 
study, we assigned each child an equal prior probability of etiology 
for each of the 33 pathogens tested by PCR and generated pos-
terior probabilities based on the individual pattern of test results 
so that a cause was assigned for every case. This novel approach 
provides an indication of viral etiology in a much larger propor-
tion of cases. This, in turn, presents a clinical challenge to identify, 
FIGURE 1. Recruitment flow chart. Left, Case recruitment. Right, Control recruitment.
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at presentation, the minority of children with a bacterial cause in 
order to target antibiotic treatment appropriately. 
Compared with the pilot study, the main study also illustrates a 
significant change in the blood culture test results; the yield of pneu-
mococci from blood cultures fell from 4% in the pilot study to 0.8% 
in the main study. Although blood culture is an insensitive method to 
define etiology, the reduction in test positivity is consistent with the 
declining incidence of S. pneumoniae disease following pneumococcal 
vaccine introduction.6,7 PCV10 was introduced in January 2011, imme-
diately after the pilot study terminated, with a catch-up campaign that 
reached two-thirds of all children <5 years of age in Kilifi County by 
March 20117; the PERCH study began in August 2011. Interrupted time 
series analyses, centered on PCV10 introduction, estimated that the inci-
dence of admission with WHO-defined severe or very severe pneumo-
nia and radiologically confirmed pneumonia declined by 27% and 48%, 
respectively.7 Of note, the radiologic definition in this impact study was 
TABLE 1. Demographic Characteristics of HIV-Uninfected Cases and Controls
 
All Cases (N = 630*) CXR Abnormal† (N = 282*) CXR Normal (N = 284*) Controls (N = 863*)
n (%) n (%) n (%) n (%)
Age     
  28 days to 5 m 209 (33) 90 (32) 86 (30) 234 (27)
  6–11 m 130 (21) 66 (23) 51 (18) 190 (22)
  12–23 m 167 (27) 79 (28) 78 (28) 247 (29)
  24–59 m 124 (20) 47 (17) 69 (24) 192 (22)
Sex     
  Male 369 (59) 152 (54) 179 (63) 452 (52)
  Female 261 (41) 130 (46) 105 (37) 410 (48)
Season of enrolment     
  Rainy (Apr to Jul, Oct to Dec) 374 (60) 166 (59) 167 (59) 478 (55)
  Dry (Jan to Mar, Aug to Sep) 256 (41) 116 (41) 117 (41) 385 (45)
HIV exposure status     
  Exposed‡ 71 (11) 34 (12) 30 (11) 144 (17)
  Unexposed 559 (89) 248 (88) 254 (89) 719 (83)
Malaria slide     
  Negative 583 (93) 271 (97) 252 (89) 797 (98)
  Positive 43 (7) 9 (3) 30 (11) 15 (2)
Mid upper arm circumference§     
  ≥11.5 cm 370 (89) 166 (87) 178 (90) 611 (99)
  <11.5 cm 48 (12) 24 (13) 19 (10) 8 (1)
Weight-for-height Z scores     
  >−2 425 (70) 177 (66) 207 (75) 801 (94)
  −3 to −2 105 (18) 56 (21) 36 (13) 30 (4)
  <−3 74 (12) 36 (13) 33 (12) 22 (3)
Weight-for-age Z scores     
  >−2 358 (57) 146 (52) 172 (61) 710 (83)
  −3 to −2 131 (21) 65 (23) 56 (20) 109 (13)
  <−3 135 (22) 68 (24) 53 (19) 38 (4)
Height-for-age Z scores     
  >−2 383 (63) 158 (58) 184 (66) 508 (59)
  −3 to −2 124 (20) 68 (25) 48 (17) 173 (20)
  <−3 104 (17) 47 (17) 47 (17) 178 (21)
PCV10 vaccination status¶     
  None 53 (9) 14 (5) 24 (9) 34 (4)
  Fully vaccinated (<1 year) 287 (85) 136 (87) 117 (85) 392 (93)
  Fully vaccinated (≥1 year) 211 (75) 93 (75) 106 (75) 330 (78)
Pentavalent vaccination status║     
  None 40 (6) 11 (4) 16 (6) 13 (2)
  Fully vaccinated (<1 year) 277 (82) 133 (86) 111 (81) 387 (92)
  Fully vaccinated (≥1 year) 273 (97) 117 (95) 141 (99) 405 (96)
Serum antibiotic activity     
  No 485 (87) 233 (90) 207 (86) 754 (97)
  Yes 73 (13) 26 (10) 35 (15) 21 (3)
Parental report of antibiotic use     
  No 310 (56) 125 (52) 157 (62) 839 (97)
  Yes 242 (44) 116 (48) 98 (38) 24 (3)
Prior exposure to antibiotics**     
  No 317 (58) 155 (61) 132 (56) 752 (97)
  Yes 229 (42) 99 (39) 104 (44) 21 (3)
*Restricted to HIV-uninfected participants.
†CXR abnormal defined as chest radiograph finding: consolidation or any other infiltrate.
‡Maternal report of being HIV positive during pregnancy and ELISA results either missing, negative or positive without confirmatory virology test results.
§Restricted to children ≥6 months of age.
¶For children <1 year of age, defined as ≥1 dose and up-to-date for age at enrollment, doses received, and Kenya EPI schedule (allowing 4-week window each for dose). For chil-
dren ≥1 year of age, defined as 2 doses if given ≥8 weeks apart and child was >1 year of age at first dose; 1 dose if age at any dose or age at introduction was >2 years.
║For children <1 year of age, defined as ≥1 dose and up-to-date for age at enrollment, doses received, and Kenya EPI schedule (allowing 4-week window each for dose). For chil-
dren ≥1 year of age, defined as 3 doses.
**Defined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic administration before whole blood specimen collection at 
the study facility (cases only); restricted to children with blood specimen collected.
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TABLE 2. Clinical Characteristics of HIV-Uninfected Cases
 








CXR Other  
Infiltrate  










Died in  
Hospital 
(N = 33)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age   
  28 days to 5 months 209 (33) 90 (32) 49 (41) 41 (25) 86 (30) 114 (37) 95 (29) 15 (46)
  6–11 months 130 (21) 66 (23) 20 (17) 46 (28) 51 (18) 73 (24) 57 (18) 5 (15)
  12–23 months 167 (27) 79 (28) 26 (22) 53 (33) 78 (28) 68 (22) 99 (31) 9 (27)
  24–59 months 124 (20) 47 (17) 14 (12) 23 (14) 69 (24) 52 (17) 72 (22) 4 (12)
 Female 261 (41) 130 (46) 58 (49) 72 (44) 105 (37) 126 (41) 135 (42) 20 (61)
 Very severe pneumonia 323 (51) 114 (40) 55 (46) 59 (36) 173 (61) 0 (0) 323 (100) 22 (67)
Case fatality   
  Died in hospital 33 (5) 17 (6) 12 (10) 5 (3) 9 (3) 11 (4) 22 (7) 33 (100)
  Died within 30 days of discharge 6 (1) 1 (0.4) 1 (0.8) 0 (0) 3 (1) 3 (1) 3 (1) 0 (0)
Chest radiograph findings†   
  Taken within 72 h 594 (94) 282 (100) 119 (100) 163 (100) 284 (100) 291 (95) 303 (94) 28 (85)
   Consolidation 119 (19) 119 (42) 119 (100) 0 (0) 0 (0) 64 (21) 55 (17) 12 (36)
   Other infiltrate only 163 (26) 163 (58) 0 (0) 163 (100) 0 (0) 104 (34) 59 (18) 5 (15)
   Normal 284 (45) 0 (0) 0 (0) 0 (0) 284 (100) 111 (36) 173 (54) 9 (27)
   Uninterpretable 28 (4) 0 (0) 0 (0) 0 (0) 0 (0) 12 (4) 16 (5) 2 (6)
  Not taken 28 (4) 0 (0) 0 (0) 0 (0) 0 (0) 10 (3) 18 (6) 5 (15)
   Child died 5 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.3) 4 (1) 5 (15)
   Other reasons 23 (4) 0 (0) 0 (0) 0 (0) 0 (0) 9 (3) 14 (4) 0 (0)
Clinical characteristics   
  Lower chest wall indrawing 492 (78) 259 (92) 110 (92) 149 (91) 186 (65) 307 (100) 186 (57) 28 (85)
  Hypoxemia‡ 185 (29) 106 (38) 57 (48) 49 (30) 52 (18) 75 (24) 109 (34) 18 (55)
  Oxygen use at admission 132 (21) 75 (27) 42 (35) 33 (20) 36 (13) 44 (14) 88 (27) 14 (42)
  Tachypnoea 439 (70) 224 (79) 99 (83) 125 (77) 174 (61) 231 (75) 208 (64) 25 (76)
  Tachycardia 349 (55) 166 (59) 77 (65) 89 (55) 145 (51) 165 (54) 184 (57) 18 (55)
  Central cyanosis 5 (0.8) 1 (0.4) 0 (0) 1 (0.6) 3 (1) 0 (0) 5 (2) 3 (9)
  Convulsions 89 (14) 16 (6) 4 (3) 12 (7) 61 (22) 1§ (0.3) 88 (27) 5 (15)
  Lethargy 144 (23) 55 (20) 27 (23) 28 (17) 72 (25) 0 (0) 144 (45) 13 (39)
  Unable to feed 78 (12) 36 (13) 22 (19) 14 (9) 28 (10) 0 (0) 67 (21) 3 (9)
  Vomiting 67 (11) 14 (5) 6 (5) 8 (5) 44 (16) 0 (0) 67 (21) 3 (9)
  Crackles 247 (39) 134 (48) 60 (50) 74 (45) 87 (31) 124 (40) 123 (38) 12 (36)
  Audible wheeze 29 (5) 13 (5) 4 (3) 9 (6) 15 (5) 19 (6) 10 (3) 1 (3)
  Wheeze on auscultation 83 (13) 41 (15) 15 (13) 26 (16) 39 (14) 49 (16) 34 (11) 4 (12)
  Grunting 40 (6) 23 (8) 11 (9) 12 (7) 12 (4) 12 (4) 28 (9) 4 (12)
  Nasal flaring 317 (50) 166 (59) 76 (64) 90 (55) 119 (42) 162 (53) 155 (48) 20 (61)
  Temp >38°C 267 (42) 128 (45) 59 (50) 69 (42) 114 (40) 130 (42) 143 (44) 11 (33)
  Leukocytosis 282 (45) 145 (51) 64 (54) 81 (50) 112 (39) 139 (45) 143 (44) 11 (33)
  CRP ≥ 40 mg/dL 154 (24) 78 (28) 46 (39) 32 (20) 66 (23) 71 (23) 83 (26) 10 (30)
Hemoglobin    
  ≤7.5 g/dL 83 (13) 47 (17) 21 (18) 26 (16) 30 (11) 38 (12) 45 (14) 6 (18)
  >7.5 g/dL 536 (85) 231 (82) 98 (83) 133 (82) 248 (88) 264 (86) 272 (84) 27 (82)
 Malaria slide positive 43 (7) 9 (3) 3 (3) 6 (4) 30 (11) 6 (2) 37 (12) 1 (3)
HIV exposure status    
  Exposed 4 (0.6) 1 (0.4) 0 (0) 1 (0.6) 3 (1) 0 (0) 4 (1) 2 (6)
  Unexposed 559 (89) 248 (88) 101 (85) 147 (90) 254 (89) 273 (89) 286 (89) 23 (70)
  Unknown 67 (11) 33 (12) 18 (15) 15 (9) 27 (10) 34 (11) 33 (10) 8 (24)
 MUAC < 11.5 cm║ 48 (12) 24 (13) 8 (11) 16 (13) 19 (10) 21 (11) 27 (12) 6 (33)
Weight-for-height Z scores    
  >−2 425 (70) 177 (66) 70 (61) 107 (69) 207 (75) 213 (72) 212 (68) 15 (52)
  −3 to ≤−2 105 (18) 56 (21) 28 (25) 28 (18) 36 (13) 48 (16) 57 (18) 7 (24)
  <−3 74 (12) 36 (13) 16 (14) 20 (13) 33 (12) 33 (11) 41 (13) 7 (24)
Weight–for-age Z scores    
  >−2 358 (57) 146 (52) 54 (45) 92 (58) 172 (61) 178 (59) 180 (56) 7 (22)
  −3 to ≤−2 131 (21) 65 (23) 27 (23) 38 (24) 56 (20) 63 (21) 68 (21) 8 (25)
  <−3 135 (22) 68 (24) 38 (32) 30 (19) 53 (19) 62 (20) 73 (23) 17 (53)
Height-for-age Z scores    
  >−2 383 (63) 158 (58) 61 (53) 97 (62) 184 (66) 185 (63) 198 (63) 9 (29)
  −3 to ≤−2 124 (20) 68 (25) 30 (26) 38 (24) 48 (17) 64 (22) 60 (19) 8 (26)
  <−3 104 (17) 47 (17) 25 (22) 22 (14) 47 (17) 47 (16) 57 (18) 14 (45)
Duration of illness**    
  0–2 days 241 (38) 99 (35) 35 (29) 64 (39) 118 (42) 114 (37) 127 (39) 7 (21)
  3–5 days 268 (43) 130 (46) 56 (47) 74 (45) 111 (39) 134 (44) 134 (42) 11 (33)
  >5 days 121 (19) 53 (19) 28 (24) 25 (15) 55 (19) 59 (19) 62 (19) 15 (46)
Duration of hospitalization   
  0–2 days 196 (31) 68 (24) 23 (19) 45 (28) 106 (37) 93 (30) 103 (32) 15 (45)
  3–5 days 303 (48) 138 (49) 53 (45) 85 (52) 141 (50) 151 (49) 152 (47) 8 (24)
  >5 days 131 (21) 76 (27) 43 (36) 33 (20) 37 (13) 63 (21) 68 (21) 10 (30)
Antibiotic use   
  Prior exposure to antibiotics†† 229 (42) 99 (39) 42 (39) 57 (39) 104 (44) 111 (41) 118 (43) 7 (27)
  Parental report of antibiotic use before hospitalization 242 (44) 116 (48) 52 (50) 64 (47) 98 (38) 117 (44) 125 (44) 10 (34)
*CXR abnormal defined as consolidation and/or other infiltrate.
†Eight cases had a CXR obtained more than 3 days after enrollment and their CXR findings were not used in analyses. Other reasons no CXR available included child discharged or absconded 
before CXR (N = 9), operator error (N = 1), transferred to another facility (N = 1) and other reasons (N = 12).
‡Hypoxemia defined as oxygen saturation <92% or on supplemental oxygen if a room air oxygen saturation reading was not available (N = 53).
§Single brief convulsion without other very severe case-defining signs.
¶Elevated white blood cells defined as >15 × 109 cells/L for children 1–11 months and >13 × 109 cells/L for children 12–59 months.
║Restricted to children ≥6 months of age.
**Duration of illness defined as maximum days of reported symptoms for any of the following: cough, wheeze, fever or difficulty breathing.
††Defined as serum bioassay positive (cases and controls), antibiotics administered at the referral facility, or antibiotic administration before whole blood specimen collection at the study 
facility (cases only); restricted to children with blood specimen collected.
CRP indicates C-reactive protein; MUAC, mid upper arm circumference.
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FIGURE 2. Top 10 causes of radiologically 
confirmed pneumonia in HIV-uninfected cases, 
stratified by age, severity and CXR findings. 
Radiologically confirmed pneumonia defined 
by the presence of any of consolidation, pleural 
effusion or other infiltrate on chest radiograph. 
Description of symbols: Line represents the 
95% credible interval. The size of the symbol 
is scaled based on the ratio of the estimated 
etiologic fraction to its standard error. Of 2 
identical etiologic fraction estimates, the estimate 
associated with a larger symbol is more informed 
by the data than the priors. Panel C Stratified by 
WHO 2005 pneumonia case classification: severe 
pneumonia, cough or difficulty in breathing 
and lower chest wall indrawing without any 
danger sign; and very severe pneumonia, 
cough or difficulty in breathing and any danger 
sign. Flu indicates influenza virus A, B and C; 
H. inf, Haemophilus influenzae; HMPV, human 
metapneumovirus A/B; Mtb, Mycobacterium 
tuberculosis; NoS, not otherwise specified (ie, 
pathogens not tested for); P. jirov, P. jirovecii; 
Para, parainfluenza virus types 1, 2, 3 and 4; PV/
EV, parechovirus/enterovirus; Rhino, Human 
rhinovirus; S. pneu, Streptococcus pneumoniae.
continued
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restricted to consolidation and/or effusion,7,35 whereas 
the definition used in PERCH also included abnormal 
infiltrates. However, given these substantial changes in 
pneumonia incidence attributable to a single pathogen 
vaccine, it is not surprising that the contribution of bac-
teremic pneumococcal pneumonia appears considerably 
reduced in PERCH compared with the pilot study.
RSV was the commonest viral cause of pneu-
monia cases in Kilifi and in all of the other PERCH 
sites. Previous studies in Kilifi identified an associa-
tion between RSV infection in the nasopharynx and 
admission with pneumonia34,36; the prevalence of 
nasopharyngeal infection was 12%–27% among hos-
pitalized pneumonia cases, 16% among outpatient 
controls with upper respiratory tract infections and 
2% among healthy controls.16,34,36 RSV infections are 
associated with low (2.4%) mortality at KCH.16 In the 
PERCH study in Kilifi, the CFRs (estimated using 
the integrated analysis) for RSV and for all other 
pneumonias were 1.6% (95% CrI: 0–4.4) and 8.1% 
(95% CrI: 6.4–9.6), respectively. Although 37% 
of pneumonia was attributed to RSV, the low CFR 
estimate suggests that RSV is responsible for only a 
small fraction of pneumonia deaths in Kilifi.
Rhinovirus was a common infection at all 
sites with a prevalence of 17%–36% in cases and 
14%–26% in controls. However, it was significantly 
associated with case status in only 2 countries; Kenya 
(OR 2.4, 95% CI 1.6, 3.7) and Bangladesh (OR 2.5, 
95% CI 1.7, 3.7). The prevalence of rhinovirus varies 
across time and place, as does the evidence implying 
a causal role. In the Kilifi pilot study, for example, 
the prevalence of rhinovirus in NP specimens was 
23% and 22% in hospitalized cases of WHO-defined 
pneumonia and outpatient controls without pneumo-
nia, respectively (OR 1.0, 95% CI 0.7, 1.3).34 In the 
South Africa site of the PERCH study, the prevalence 
of rhinovirus in cases and controls was 19% and 22%, 
respectively (OR = 1.0, 95% CI: 0.5–1.9). However, 
in a separate study in South Africa at the same time, 
rhinovirus was found in 40% of children <5 years of 
age admitted with severe acute respiratory illness and 
33% of outpatient controls without respiratory symp-
toms (aRR = 1.8, 95% CI: 1.4–2.3).37 It is not yet clear 
whether rhinovirus is a direct lung pathogen or acts 
synergistically to precipitate pneumonia caused by 
other pathogens or is falsely implicated by confound-
ing. For example, children from crowded households 
are more likely than those from uncrowded house-
holds to be exposed to infections of the upper and of 
the lower respiratory tract, generating an association 
between crowding and pneumonia and an independ-
ent association between crowding and pathogens in 
the upper respiratory tract.
The WHO clinical definitions of pneumonia 
were designed to favor sensitivity over specificity in 
order to make life-saving antibiotics widely acces-
sible. In the primary PERCH analysis, we increased 
our specificity by analyzing only cases with abnor-
mal CXRs. In Kilifi, we also explored the specific-
ity of these case definitions through an analysis of 
the discharge diagnoses among different sub-groups 
FIGURE 2. continued 
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of PERCH patients (Table, Supplemental Digital Content 10, 
http://links.lww.com/INF/D880). These discharge diagnoses were 
not part of the PERCH protocol and no attempt was made to stand-
ardize interpretations or validate the results. Clinicians identified 
non-LRTI conditions in the discharge diagnosis in over a quarter 
of all PERCH cases, rising to 42% among very severe pneumonia 
cases. Common primary discharge diagnoses for these patients 
were malaria (7%), gastroenteritis (5%), malnutrition (4%), febrile 
convulsions (3%) and upper respiratory tract infection (2%) illus-
trating the considerable overlap in clinical presentations between 
common pediatric conditions and the limitations of a case defini-
tion focused on admission features alone. The clinicians also did 
not mention LRTI in the discharge diagnosis of 42 PERCH cases 
later classified as having abnormal CXRs by the reading panel, 
19 of these had infiltrates only (Table, Supplemental Digital Con-
tent 10, http://links.lww.com/INF/D880). Some of the diagnoses 
given, including paraffin poisoning (n = 3) and bronchiolitis (n = 
4), are compatible with CXR abnormalities. Some children with 
predisposition to recurrent pneumonia due to chronic conditions 
(eg, congenital heart disease, malnutrition, sickle cell disease) 
may have had CXR changes from previous pneumonia episodes.38 
The attending pediatrician may have interpreted the radiographs as 
negative for pneumonia. Alternatively, the diagnoses selected may 
have simply “trumped” pneumonia in a system that only allows 
the clinician to specify 2 conditions: combinations of malnutrition, 
malaria, anemia, febrile convulsions, pulmonary TB, immunosup-
pression, sepsis, sickle cell disease or meningitis account for 15 
of these cases. While the WHO clinical case definitions are essen-
tial in case management, they do not always capture the dominant 
pathology or illness in a sick child.
Two limitations of this study are noteworthy. The first is 
its focus on hospitalized cases.39 Studies from Kilifi have already 
documented poor access to care: for example, approximately 
40% of very severe pneumonia cases occurring in KHDSS do 
not seek care at the study hospital40 and 64% of all childhood 
deaths occur outside the hospital.18 The etiology of pneumonia 
among cases that do not seek care may differ markedly from 
the patterns documented here. Second, available pneumonia 
etiology evidence and analytic methods may underestimate the 
role of bacteria in pneumonia etiology. Much of the pathologic 
evidence for etiology in pneumonia studies comes from naso-
pharynx,34,41–43 which is frequently colonized by organisms in 
the absence of pneumonia. In Kilifi, we have little evidence 
from the anatomic site of pathology as we cultured only 3 pleu-
ral fluid aspirates and no lung aspirates. Blood cultures were 
performed in most children and the PIA model does adjust for 
sensitivity and the impact of antibiotics, which were measured 
FIGURE 3. Primary discharge diagnoses for children 28 days to 59 months of age admitted at the study hospital during 
the PERCH study. WHO Pneumonia classification (2005): severe pneumonia, cough or difficulty in breathing and lower 
chest wall indrawing without any danger sign; and very severe pneumonia, cough or difficulty in breathing and any danger 
sign. Abnormal chest radiograph: presence of any of consolidation, pleural effusion or other infiltrate on chest radiograph. 
Discharge diagnoses (primary and secondary) are recorded in a standard computer form at discharge by nonstudy clinicians 
during discharge. The most appropriate diagnoses are selected from a predefined list based on the diagnosis recorded 
during the course of the admission. At the study hospital bronchiolitis is differentiated at discharge diagnosis as part of a 
longitudinal surveillance program in Kilifi for RSV. In PERCH, children with wheeze/bronchiolitis were excluded from the 
study only if their case-defining symptoms (usually lower chest wall indrawing) resolved after bronchodilator treatment.
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using a bioassay of serum.29 However, the biologic detection of 
antibiotic exposure is insensitive to antibiotics administered ≥8 
hours previously because of their short serum half-life. Paren-
tal reports of antibiotic administration were much higher than 
antibiotics detected in the serum (Table 1), but parental report is 
also not a reliable measure.
The PERCH study integrated results from multiple sample 
sites from both cases and controls using partial latent class analy-
sis and a Bayesian analytical approach to provide an estimate of 
pneumonia etiology in children in Kilifi. Based on these analyses, 
77% of the etiology of pneumonia was attributable to viruses, par-
ticularly RSV and rhinovirus. This emphasizes the need to advance 
vaccines against RSV in children and to understand the pathogen-
esis of pneumonia involving viral infections. It also significantly 
reduces the likelihood that antibiotics will alter the course of 
pneumonia illness in a hospitalized child and sets out a significant 
challenge to identify the minority of hospitalized cases who do 
require antibiotics. The prevalence of bacteremic pneumococcal 
pneumonia has declined between the pilot study in 2010 and the 
main PERCH study in 2011 to 2013 and this can probably best be 
explained by the significant impact of PCV10 on the incidence of 
pneumococcal pneumonia.
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